Syndicated Report

CAR T-Cell Therapy Perceptions

October 26, 2021

Subsequent to a report of a chromosomal abnormality in CAR T-cells in a patient treated in an allogeneic CAR T-cell therapy clinical trial, the FDA has placed a hold on allogeneic CAR T-cell therapy clinical trials being conducted by that company.

InCrowd wanted to understand how this FDA action affected oncologists’ and hematologists’ perceptions of CAR T-cell therapy in both the allogeneic and autologous spaces and gene therapy in general.

Download the latest InCrowd Instant Insights report to learn how 76 US oncologists, hematologists, and hematology-oncologists felt about the future of CAR T-Cell therapy and the impact of FDA actions on their perceptions of gene therapy. 

    InCrowd uses the information you provide to us to contact you about our relevant insights, products, and services. You may opt out of communications at any time via the unsubscribe link at the bottom of any email or by sending an email withdrawing your consent to Send Email. For more information, please review our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.